Oncoinvent ASA ("Oncoinvent" or the "Company") Primary insider Anne Cecile
Alvik, Head of QA and Board member (employee representative) of Oncoinvent ASA,
has 5. March 2025 acquired 8 500 shares in Oncoinvent ASA at an average price of
NOK 1,694 per share. Following this transaction, Anne Cecilie owns 13 200 shares
in Oncoinvent ASA.
This information is subject to the disclosure requirements pursuant to article
19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section
5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing
innovative treatments for solid cancers. The technology platform is focused on
the use of alpha-emitting radionuclides to deliver powerful radiation directly
to cancer cells. The Company's lead product candidate, Radspherin®, is being
advanced through clinical development by a team with experience from all stages
of radiopharmaceutical development. Internal manufacturing and supply chain
capabilities have been established, which now have the capacity to supply
Radspherin® for multi-center phase 2 clinical studies.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com